OA13013A - Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. - Google Patents
Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. Download PDFInfo
- Publication number
- OA13013A OA13013A OA1200500169A OA1200500169A OA13013A OA 13013 A OA13013 A OA 13013A OA 1200500169 A OA1200500169 A OA 1200500169A OA 1200500169 A OA1200500169 A OA 1200500169A OA 13013 A OA13013 A OA 13013A
- Authority
- OA
- OAPI
- Prior art keywords
- degrees
- expressed
- strontium ranelate
- strokes
- crystalline form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0410335A FR2875807B1 (fr) | 2004-09-30 | 2004-09-30 | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA13013A true OA13013A (fr) | 2006-11-10 |
Family
ID=34942420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200500169A OA13013A (fr) | 2004-09-30 | 2005-06-02 | Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. |
Country Status (42)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| US20070292529A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating osteoporotic conditions |
| US20070292535A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating arthritic and or osteoporitic conditions |
| CN101206208B (zh) * | 2006-12-19 | 2011-08-10 | 北京德众万全药物技术开发有限公司 | 一种用hplc法分析雷尼酸锶原料及其制剂的方法 |
| EP2346846A1 (en) | 2008-09-29 | 2011-07-27 | Ratiopharm GmbH | Anhydrate and hydrate forms of strontium ranelate |
| IT1398542B1 (it) | 2010-03-05 | 2013-03-01 | Chemelectiva S R L | Processo per la preparazione di un polimorfo |
| CN102241663B (zh) * | 2010-05-10 | 2013-02-13 | 山东方明药业集团股份有限公司 | 一种雷奈酸锶八水合物的制备方法 |
| WO2012143932A1 (en) * | 2011-04-21 | 2012-10-26 | Shilpa Medicare Limited | Crystalline strontium ranelate form-s |
| CZ2011320A3 (cs) | 2011-05-30 | 2012-12-12 | Zentiva, K.S. | Stabilní krystalická forma X stroncium ranelátu |
| EP2530068A1 (en) | 2011-05-31 | 2012-12-05 | Lacer, S.A. | New strontium salts, synthesis and use thereof in the treatment of osteoporosis |
| US9301945B2 (en) | 2011-07-21 | 2016-04-05 | Emory University | Methods for treating inflammatory conditions and states, and cancers by antagonizing NF-κB activation |
| CN102503931A (zh) * | 2011-09-20 | 2012-06-20 | 浙江华海药业股份有限公司 | 一种雷尼酸锶晶形h的制备方法 |
| WO2013113319A1 (en) * | 2012-01-31 | 2013-08-08 | Pharmathen S.A. | Process for the preparation of strontium ranelate, intermediate or hydrates thereof |
| EP2641905A1 (en) | 2012-03-23 | 2013-09-25 | Urquima S.A. | Solid forms of strontium ranelate and processes for their preparation |
| US8569514B1 (en) | 2012-05-17 | 2013-10-29 | Divi's Laboratories, Ltd. | Process for the preparation of strontium ranelate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2651497B1 (fr) * | 1989-09-01 | 1991-10-25 | Adir | Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| PL181304B1 (pl) | 1994-07-22 | 2001-07-31 | Lilly Co Eli | Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL |
| FR2749759B1 (fr) * | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
| DE19642451A1 (de) | 1996-10-15 | 1998-04-16 | Merck Patent Gmbh | Aminothiophencarbonsäureamide |
| IL161164A0 (en) * | 2001-10-03 | 2004-08-31 | Teva Pharma | Preparation of levofloxacin and forms thereof |
| EP2272501B1 (en) * | 2002-01-09 | 2013-03-20 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate |
| JP2006508909A (ja) * | 2002-08-06 | 2006-03-16 | テバ ファーマシューティカル インダストリーズ リミティド | ガチフロキサシンの新規な結晶形 |
| FR2844797B1 (fr) * | 2002-09-24 | 2004-10-22 | Servier Lab | Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
| FR2844796A1 (fr) * | 2002-09-24 | 2004-03-26 | Servier Lab | Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
| FR2844795B1 (fr) | 2002-09-24 | 2004-10-22 | Servier Lab | Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates |
| FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
-
2004
- 2004-09-30 FR FR0410335A patent/FR2875807B1/fr not_active Expired - Fee Related
-
2005
- 2005-05-24 PE PE2005000574A patent/PE20060364A1/es not_active Application Discontinuation
- 2005-05-26 MA MA28300A patent/MA27815A1/fr unknown
- 2005-05-27 GT GT200500130A patent/GT200500130A/es unknown
- 2005-05-30 CA CA002508824A patent/CA2508824C/fr not_active Expired - Fee Related
- 2005-05-31 US US11/140,822 patent/US7459568B2/en not_active Expired - Fee Related
- 2005-05-31 AP AP2005003323A patent/AP1930A/xx active
- 2005-06-02 OA OA1200500169A patent/OA13013A/fr unknown
- 2005-06-14 AR ARP050102423A patent/AR049395A1/es not_active Application Discontinuation
- 2005-06-15 CR CR7876A patent/CR7876A/es not_active Application Discontinuation
- 2005-06-15 MX MXPA05006407A patent/MXPA05006407A/es active IP Right Grant
- 2005-06-15 SA SA05260168A patent/SA05260168B1/ar unknown
- 2005-06-16 CN CNB2005100753929A patent/CN100391956C/zh not_active Expired - Fee Related
- 2005-06-16 EC EC2005005859A patent/ECSP055859A/es unknown
- 2005-06-16 CO CO05058754A patent/CO5710195A1/es not_active Application Discontinuation
- 2005-06-16 IL IL169237A patent/IL169237A/en not_active IP Right Cessation
- 2005-06-17 EP EP08007270A patent/EP1944302A1/fr not_active Withdrawn
- 2005-06-17 JP JP2005177199A patent/JP2006104184A/ja active Pending
- 2005-06-17 PT PT05291297T patent/PT1642897E/pt unknown
- 2005-06-17 NO NO20052998A patent/NO333948B1/no not_active IP Right Cessation
- 2005-06-17 SG SG200503938A patent/SG121035A1/en unknown
- 2005-06-17 WO PCT/FR2005/001515 patent/WO2006035122A1/fr active Application Filing
- 2005-06-17 AT AT05291297T patent/ATE411308T1/de active
- 2005-06-17 TW TW094120331A patent/TWI367881B/zh not_active IP Right Cessation
- 2005-06-17 BR BRPI0502228-2A patent/BRPI0502228A/pt not_active IP Right Cessation
- 2005-06-17 DE DE602005010359T patent/DE602005010359D1/de active Active
- 2005-06-17 PL PL05291297T patent/PL1642897T3/pl unknown
- 2005-06-17 SI SI200530490T patent/SI1642897T1/sl unknown
- 2005-06-17 UA UAA200505970A patent/UA80008C2/ru unknown
- 2005-06-17 RS RSP-2008/0506A patent/RS51110B/sr unknown
- 2005-06-17 NZ NZ540802A patent/NZ540802A/en not_active IP Right Cessation
- 2005-06-17 EA EA200500842A patent/EA008474B1/ru not_active IP Right Cessation
- 2005-06-17 AU AU2005202718A patent/AU2005202718B2/en not_active Ceased
- 2005-06-17 ES ES05291297T patent/ES2314593T3/es active Active
- 2005-06-17 ZA ZA200504937A patent/ZA200504937B/en unknown
- 2005-06-17 EP EP05291297A patent/EP1642897B9/fr not_active Revoked
- 2005-06-17 DK DK05291297T patent/DK1642897T3/da active
- 2005-06-17 GE GEAP20058848A patent/GEP20074106B/en unknown
- 2005-07-01 PA PA20058638201A patent/PA8638201A1/es unknown
- 2005-07-08 KR KR1020050061542A patent/KR100816590B1/ko not_active IP Right Cessation
-
2006
- 2006-05-29 HK HK06106187A patent/HK1086260A1/xx not_active IP Right Cessation
-
2008
- 2008-08-12 US US12/228,381 patent/US7745482B2/en not_active Expired - Fee Related
- 2008-11-19 CY CY20081101327T patent/CY1108797T1/el unknown
- 2008-12-16 HR HR20080652T patent/HRP20080652T3/xx unknown
-
2010
- 2010-01-07 JP JP2010001847A patent/JP2010132669A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA13013A (fr) | Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. | |
| CA2537414C (fr) | Forme cristalline .beta. du chlorhydrate de l'ivrabadine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| CA2537404C (fr) | Forme cristalline .gamma.-d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| CA2537400C (fr) | Forme cristalline .gamma. du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| CA2537420C (fr) | Forme cristalline bd du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| CA2564367C (fr) | Forme cristalline .delta. du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| CA2564369C (fr) | Forme cristalline .delta.d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| EP1296947B1 (fr) | Forme cristalline alpha du sel de tert-butylamine du perindopril | |
| WO2001083439A2 (fr) | NOUVELLE FORME CRISTALLINE η DU SEL DE TERT-BUTYLAMINE DU PERINDOPRIL, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT | |
| WO2001087836A1 (fr) | Nouvelle forme cristalline $g(b) du sel de tert-butylamine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| FR3025197B1 (fr) | Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |